# Exercise as an Immune Adjuvant for Allogeneic Cell Therapies

> **NCT06643221** · EARLY_PHASE1 · RECRUITING · sponsor: **University of Arizona** · enrollment: 100 (estimated)

## Conditions studied

- Leukemia
- Hematopoetic Stem Cell Transplantation
- Donor Lymphocyte Infusion
- CAR T-Cell Therapy
- Lymphoma
- Cell Therapy

## Interventions

- **BEHAVIORAL:** Exercise
- **DRUG:** Isoproterenol
- **DRUG:** Placebo
- **DRUG:** Bisoprolol Fumarate Tablet 10 mg
- **DRUG:** Nadolol (1 x 80 mg) Tablets (Invamed, Inc)
- **DRUG:** Carvedilol 50 mg
- **DRUG:** Roflumilast 500 Mcg Oral Tablet

## Key facts

- **NCT ID:** NCT06643221
- **Lead sponsor:** University of Arizona
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2018-01-24
- **Primary completion:** 2028-12-30
- **Final completion:** 2028-12-30
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2024-10-16

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06643221

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06643221, "Exercise as an Immune Adjuvant for Allogeneic Cell Therapies". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT06643221. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*